Acute pancreatitis as an uncommon manifestation of systemic lupus erythematosus with overlapping Sjögren’s syndrome
DOI:
https://doi.org/10.32818/reccmi.a10n2a17Keywords:
acute pancreatitis, systemic lupus erythematosus, Sjögren’s syndrome, overlap syndromeAbstract
Lupus pancreatitis is a rare and potentially severe complication of systemic lupus erythematosus (SLE). We report the case of a 23-year-old woman presenting with epigastric pain, vomiting, and abdominal distension. Clinical and laboratory findings revealed acute pancreatitis with no identifiable cause. Given additional systemic symptoms, an autoimmune workup confirmed SLE with overlapping Sjögren’s syndrome. This case highlights the importance of considering autoimmune etiologies in atypical pancreatitis, as timely diagnosis and appropriate immunosuppressive treatment can significantly improve patient outcomes.
Downloads
Metrics
References
Blanco-Ornelas LH, Martín-Nares E, Aguirre-Muñoz MA, Valerdi-Contreras L. Pancreatitis aguda como presentación inicial de lupus eritematoso sistémico. Rev Med MD. 2016; 78(3): 196-99. Accesible en: https://www.medigraphic. com/cgi-bin/new/resumen.cgi?IDARTICULO=65578 (último acceso ago. 2025).
Gianordoli APE, Laguardia RVRB, Santos MCFS, Jorge FC, da Silva Salomão A, Caser LC, et al. Prevalence of Sjögren's syndrome according to 2016 ACR-EULAR classification criteria in patients with systemic lupus erythematosus. Adv Rheumatol. 2023; 63(1): 11. doi: https://doi.org/10.1186/s42358-022- 00280-1 (último acceso ago. 2025). DOI: https://doi.org/10.1186/s42358-022-00280-1
Cui Y, Zhang H, Wang Z, Gong B, Al-Ward H, Deng Y, et al. Exploring the shared molecular mechanisms between systemic lupus erythematosus and primary Sjögren's syndrome based on integrated bioinformatics and single-cell RNA-seq analysis. Front Immunol. 2023; 14: 1212330. doi: https:// doi.org/10.3389/fimmu.2023.1212330 (último acceso ago. 2025). DOI: https://doi.org/10.3389/fimmu.2023.1339929
Velasque Marques E, Cerqueira Batista Filho LA, Toledo Maciel A. Acute pancreatitis caused by systemic lupus erythematosus activity: a case report and literature review. Medwave. 2023; 23(7): e2684–e2684. doi: https://doi. org/10.5867/medwave.2023.07.2684 (último acceso ago. 2025). DOI: https://doi.org/10.5867/medwave.2023.07.2684
Breuer GS, Baer A, Dahan D, Nesher G. Lupus-associated pancreatitis. Autoimmun Rev. 2006; 5(5): 314-18. doi: https://doi.org/10.1016/j.au-trev.2005.11.004 (último acceso ago. 2025). DOI: https://doi.org/10.1016/j.autrev.2005.11.004
Wang Q, Shen M, Leng X, Zeng X, Zhang F, Qian J. Prevalence, severity, and clinical features of acute and chronic pancreatitis in patients with systemic lupus erythematosus. Rheumatol Int. 2016; 36(10): 1413-1419. doi: https:// doi.org/10.1007/s00296-016-3526-z (último acceso ago. 2025). DOI: https://doi.org/10.1007/s00296-016-3526-z
Makol A, Petri M. Pancreatitis in systemic lupus erythematosus: frequency and associated factors - a review of the Hopkins Lupus Cohort. J Rheuma-tol. 2010; 37(2): 341-45. doi: https://doi.org/10.3899/jrheum.090829 (último acceso ago. 2025). DOI: https://doi.org/10.3899/jrheum.090829
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(6): 736-45. doi: https:// doi.org/10.1136/annrheumdis-2019-215089 (último acceso ago. 2025). DOI: https://doi.org/10.1136/annrheumdis-2019-215089
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Bryan Astudillo-Ramírez, Tannia Aguirre-Soria
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
